Other Consolidated Financial Statement Detail

Supplemental Cash Flow Information

Supplemental disclosure of cash flow information for the years ended December 31, 2014, 2013 and 2012, is as follows:



	For the Years Ended December 31,
(In millions)	2014		2013		2012
Cash paid during the year for:
Interest	$	41.2	$	53.6	$	65.4
Income taxes	$	1,163.2	$	643.2	$	526.6

Non-cash Investing and Financing Activity

In the fourth quarter of 2014, we accrued $250.0 million upon reaching $4.0 billion in total cumulative sales of Fumapharm Products. The amount, net of tax benefit, was accounted for as an increase to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm and is expected to be paid in the first quarter of 2015. For additional information related to this transaction, please read Note 22, Commitment and Contingencies to these consolidated financial statements.

In July and November 2013, the construction of two office buildings in Cambridge, Massachusetts was completed and we started leasing the facilities. Upon completion of the construction of the buildings, we determined that we were no longer considered the owner of the buildings because we did not have any unusual or significant continuing involvement. Consequently, we derecognized the buildings and their associated financing obligation of approximately $161.5 million from our consolidated balance sheet.

In March 2012, upon completion of our acquisition of Stromedix, we recorded $219.2 million of in-process research and development and $48.2 million of goodwill. In addition, we also recorded a contingent consideration obligation of $122.2 million.

Other Income (Expense), Net

Components of other income (expense), net, are summarized as follows:



	For the Years Ended December 31,
(In millions)	2014			2013			2012
Interest income	$	12.2		$	8.2		$	29.5
Interest expense	(29.5		)	(31.9		)	(36.5		)
Impairments on investments	—			(2.8		)	(5.5		)
Gain (loss) on investments, net	11.8			21.7			10.6
Foreign exchange gains (losses), net	(11.6		)	(15.2		)	(2.5		)
Other, net	(8.7		)	(14.9		)	3.7
Total other income (expense), net	$	(25.8	)	$	(34.9	)	$	(0.7	)

Accrued Expenses and Other

Accrued expenses and other consists of the following:



	As of December 31,
(In millions)	2014		2013
Employee compensation and benefits	$	393.8	$	343.4
Revenue-related rebates	344.0		264.9
Current portion of contingent consideration obligations	265.5		54.0
Royalties and licensing fees	172.4		160.7
Deferred revenue	120.9		172.7
Clinical development expenses	65.9		55.2
Other	456.8		304.3
Total accrued expenses and other	$	1,819.3	$	1,355.2

Other Long-Term Liabilities

Other long-term liabilities consists of the following:



	As of December 31,
(In millions)	2014		2013
Employee compensation and benefits	$	200.7	$	161.5
Contingent consideration obligation	200.0		251.9
Taxes payable	142.2		177.1
Other	107.2		68.7
Total other long-term liabilities	$	650.1	$	659.2